There’s a particular kind of exhaustion that comes from trying everything you’re told to try and still not feeling better. You took the medication as prescribed. You showed up to therapy and did the work, and the heaviness is still there. If this sounds familiar, you’re not imagining things, and you’re not the exception to how depression is supposed to respond to treatment. You may simply need a treatment built for exactly this situation.
Understanding Major Depressive Disorder
Major depressive disorder (MDD) affects an estimated 21 million adults in the United States, making it one of the most widespread mental health conditions in the country. Clinically, MDD is defined by a persistent set of symptoms lasting at least two weeks, including:
- A depressed mood most of the day, almost every day
- Loss of interest or pleasure in activities once enjoyed
- Significant changes in appetite or weight
- Too much or too little sleep
- Fatigue or low energy, even after rest
- Feeling that even small tasks require extreme effort
- Difficulty concentrating or making decisions
- Feelings of worthlessness or excessive guilt
- Recurrent thoughts of death or suicide
What’s often left out of this list is how different MDD looks from person to person and how unevenly it responds to treatment. An estimated one-third of people with MDD don’t achieve adequate relief from standard antidepressants, even after trying multiple medications.
That’s not a reflection of a lack of effort, but a sign that something in the brain’s chemistry isn’t responding to the serotonin and norepinephrine pathways these medications rely on.
Spravato, a Different Kind of Treatment for a Different Kind of Depression
Spravato was built specifically for this type of depression—treatment-resistant depression and major depressive disorder with suicidal ideation. It’s an FDA-approved esketamine nasal spray, administered in a certified clinical setting under direct medical supervision, and in accordance with strict Risk Evaluation and Mitigation Strategy (REMS) guidelines.
How Spravato Works
Most antidepressants work by adjusting levels of serotonin or norepinephrine in the brain, a process that typically takes up to eight weeks to produce noticeable change. Spravato operates through an entirely different system. It targets glutamate, the brain’s most abundant neurotransmitter and a central player in how neurons communicate.
By blocking NMDA receptors, it activates the prefrontal cortex, a region of the brain closely tied to mood regulation and frequently underactive in people with depression. This supports neuroplasticity, the brain’s capacity to loosen rigid, depressive thought patterns and build new neural connections.
Benefits of Spravato for Major Depressive Disorder
Spravato has a proven track record of helping people who haven’t found relief through other available treatments. Core benefits include:
- Rapid onset: Symptom relief can begin within hours to days, compared to the several weeks typically required for SSRIs or SNRIs to take effect.
- Novel mechanism: By targeting the glutamate system instead of serotonin or norepinephrine, Spravato can help patients who haven’t responded to conventional antidepressant pathways.
- FDA-approved treatment: Spravato is FDA-approved for adults with treatment-resistant depression (TRD) and for adults with major depressive disorder (MDD) with acute suicidal ideation.
- Proven efficiency: Clinical trials show significant improvement within 24 hours in adults with suicidal ideation.
- Structured, supervised treatment: Every session takes place in a certified clinical setting with a medical team present.
- Insurance coverage: Spravato is covered by most major insurers, including BCBS, UnitedHealthcare, Aetna, and Cigna, for qualifying diagnoses.
Spravato vs. Traditional Antidepressant Therapy
If you’ve spent years cycling through SSRIs and SNRIs, it helps to see exactly where Spravato departs from that experience, and where the differences actually matter.
| Spravato | SSRIs / SNRIs | |
| How it works | Blocks NMDA receptors, increases glutamate activity, and supports neuroplasticity | Regulates serotonin or norepinephrine levels |
| Onset of effects | Hours to days | Up to 8 weeks |
| How it’s taken | Nasal spray, self-administered in a certified clinical setting | Daily oral medication, taken at home |
| Duration of treatment | Twice weekly for 4 weeks, then weekly for 4 weeks, followed by maintenance as needed | Ongoing, often for months or years |
| Best suited for | Treatment-resistant depression and MDD with suicidal ideation | Mild to moderate depression, first-line treatment |
| Insurance coverage | Covered by BCBS, UHC, Aetna, and Cigna for qualifying patients | Typically covered |
| Potential side effects | Nausea, dizziness, dissociation, and increased blood pressure | Nausea, fatigue, weight gain, and sexual dysfunction |
| Black box warning | None | Some antidepressants carry an increased risk of suicide (under 25) |
Is Spravato Right for You?
If you’ve already given oral antidepressants a fair, sustained try and you’re still waiting to feel like yourself again, that’s precisely what Spravato was designed to address. It’s not a treatment of last resort but one built on a different scientific foundation, for a form of depression that didn’t respond to traditional treatment.
Book a free consultation with our care team. Don’t look at it as a commitment to treatment (it’s not), but a chance to talk through your history with someone who understands the clinical criteria and can walk you through what Spravato actually involves, honestly and without pressure.
